Uterine cervix

• HPV E6/E7 mRNA in situ hybridization
  12 January

  HPV E6/E7 mRNA In Situ Hybridization
  Paywall references
  HPV E6/E7 mRNA In Situ Hybridization in the Diagnosis of Cervical Low-grade Squamous Intraepithelial Lesions (LSIL). Mills et al. The American Journal of Surgical Pathology: February 2018 - Volume 42 - Issue 2 - p 192–200
  doi:10.1097/PAS.0000000000000974.
  https://journals.lww.com/ajsp/Citation/2018/02000/HPV_E6_E7_mRNA_In_Situ_Hybridization_in_the.7.aspx

• microglandular hyperplasia
  11 May 2017

  cervical microglandular hyperplasia
  Cervical microglandular hyperplasia shows non neoplastic back-to-back glands with a neutrophilic infiltrate, accompanied by squamous metaplasia.
  A major clue to the diagnosis of microglandular hyperplasia is the neutrophils within the non-neoplastic glands.
  Microglandular hyperplasia shows benign back to back glands with intraluminal neutrophils.
  Differential diagnosis
  invasive endometrial carcinoma Invasive endometrial carcinoma shows malignant (...)

• cervical superficially invasive squamous cell carcinoma
  11 May 2017

  Superficially invasive squamous cell carcinoma of the cervix.
  Definition: Superficially invasive squamous cell carcinoma of the cervix is histologically defined as a superficially invasive (1-5 mm) squamous cell carcinoma.
  According to FIGO standards, superficially invasive carcinoma of the cervix is <= 5 mm depth or 7 mm width.
  Radical or modified radical hysterectomy with pelvic node dissection is usually performed for women with more than 1 mm invasion, whereas more conservative (...)

• cervical small cell carinoma
  27 March 2017

  Small cell carinoma of the cervix
  Images
  Small cell carinoma of the cervix https://twitter.com/RikiSotillo/status/844534592996605953
  See also
  small cell carcinomas
  cervical tumors cervical carcinomas

• gastric-type endocervical adenocarcinoma
  16 March 2017

  Gastric-type adenocarcinoma of the uterine cervix (GAS) is a rare variant of mucinous endocervical adenocarcinoma not etiologically associated with human papillomavirus (HPV) infection, with minimal deviation adenocarcinoma (MDA) at the well-differentiated end of the morphologic spectrum. These tumors are reported to have worse prognosis than usual HPV associated endocervical adenocarcinoma (UEA).
  Open references
  Gastric-type Endocervical Adenocarcinoma: An Aggressive Tumor With Unusual (...)

• CIN3
  7 October 2016

  WKP
  Definition: The CIN intraepithelial neoplasia is a cervical localization of squamous intraepithelial neoplasia .
  Images
  cervix uterine: CIN1 and hpv or CIN2 and hpv https://twitter.com/BellaMicheleang/status/784279836562907144
  CIN 3 Pap/Biopsy Correlation Case by Ed Euthman
  See also
  uterine cervix cervical cytology

• cervical minimal deviation adenocarcinoma
  28 September 2016

  Differential diagnosis
  lobular endocervical glandular hyperplasia
  Synopsis
  “cervical minimal deviation adenocarcinoma irregular stromal infiltration , deep invasion , desmoplastic stroma response , focally malignant cytologic features (Pathol Int 2005;55:412)

• lobular endocervical gland hyperplasia
  28 September 2016

  PO
  Differential diagnosis
  cervical minimal deviation adenocarcinoma irregular stromal infiltration, deep invasion, desmoplastic stroma response, focally malignant cytologic features (Pathol Int 2005;55:412)

• endocervical melanosis
  28 June 2016

  Images
  melanosis , endocervix , uterus https://twitter.com/dozing_dog/status/747667815117783041
  See also
  endocervical anomalies

• cervical hemangioma
  22 June 2016

  Images
  cervical hemangioma https://twitter.com/PathologyTweet/status/741665123207647232
  The vast majority of cervical hemangiomas reported are in reproductive age women. In addition, these lesions express hormone receptors, indicating that their growth is at least in part due to sex hormone stimulation.
  Although most lesions are symptomatic (mostly bleeding), the diagnosis is frequently unsuspected.
  Cervical hemangiomas are benign with no recurrences or adverse outcomes reported to (...)

0 | 10 | 20 | 30 | 40